Drug Profile

TSP 101

Alternative Names: TSP-101

Latest Information Update: 27 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Astellas Pharma
Developer Astellas Pharma; Tensegrity Pharma
Class Immunotherapies; Monoclonal antibodies
Mechanism of Action TNFRSF12A protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Cachexia
Research Immunological disorders

Most Recent Events

27 Jan 2026 Tensegrity Pharma plans a phase I/II trial (Tensegrity Pharma pipeline, January 2026)
12 Jan 2026 Adagen and Merck enters in to R&D agreement for TSP 101
12 Jan 2026 Early research in Immunological disorders in Japan (unspecified route) prior to January 2026 (tensegritypharma pipeline, January 2026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com